---
title: "Sionna Therapeutics 1Q 2026: Revenue ($27.4M), Net income ($26.78M), EPS ($0.6) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286088892.md"
description: "Sionna Therapeutics reported its 1Q 2026 results, showing revenue of $27.4M and a net income of $26.78M, with a diluted EPS of $0.6. Compared to the prior year, revenue increased by 65.6%, while net income rose by 62.5%. The company completed Phase 1 trials for SION-719 and SION-451 and is advancing to Phase 2a studies. Sionna maintains $289.9M in liquidity and has an ATM equity program to support operations through 2028."
datetime: "2026-05-12T11:21:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286088892.md)
  - [en](https://longbridge.com/en/news/286088892.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286088892.md)
---

# Sionna Therapeutics 1Q 2026: Revenue ($27.4M), Net income ($26.78M), EPS ($0.6) — 10-Q Summary

Sionna Therapeutics reported results for the first quarter of fiscal 2026 showing a wider comprehensive loss and net loss versus the prior-year quarter, with diluted loss per share roughly flat year over year.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

($27.4M)

($16.55M)

(65.6%)

Net income²

($26.78M)

($16.48M)

(62.5%)

Diluted EPS³

($0.6)

($0.62)

3.2%

_¹ Reported as “Comprehensive loss”. ² Reported as “Net loss”. ³ Reported as “loss per share, basic and diluted”._

**Business Highlights**

-   Clinical progress: Completed Phase 1 trials for SION-719 and SION-451 with favorable safety, pharmacokinetics and tablet/formulation data.
-   Advancement to later studies: Enrolled Phase 2a PreciSION CF for SION-719 and initiated a Phase 1 dual-combination study for SION-451 combinations.
-   Pipeline strategy: Pursuing NBD1 stabilizers plus complementary modulators for proprietary dual combinations or as add-ons to standard of care.
-   Operational buildout: Increased R&D and G&A headcount to support expanded clinical programs and pre-commercial activities.
-   Liquidity and funding: Maintains approximately $289.9M in liquidity and has an established ATM equity program to support operations into 2028.

Original SEC Filing: Sionna Therapeutics, Inc. \[ SION \] - 10-Q - May. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SION.US](https://longbridge.com/en/quote/SION.US.md)

## Related News & Research

- [LifeSci Capital Reaffirms Their Buy Rating on Sionna Therapeutics, Inc. (SION)](https://longbridge.com/en/news/286649459.md)
- [Sionna Therapeutics Q1 net loss widens, misses estimates](https://longbridge.com/en/news/286086578.md)
- [Pelthos Therapeutics GAAP EPS of -$3.09, revenue of $10.7M](https://longbridge.com/en/news/286430906.md)
- [Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing](https://longbridge.com/en/news/286315271.md)
- [Akari Therapeutics Delays Quarterly SEC Filing](https://longbridge.com/en/news/286828350.md)